Angiodynamics

Q4 FY2026 EarningsQ4 FY26 results beat consensus on the top line with revenue of $86.6M vs. $80.2M expected, driven by 16.7% growth in the Med Tech segment. GAAP gross margin reached 54.0%, exceeding the 52.15% estimate, aided by a favorable shift toward high-margin platforms like NanoKnife (+64.5%). While Adjusted EPS of -$0.07 beat the -$0.09 consensus, GAAP loss per share of -$0.27 missed the -$0.18 estimate due to higher restructuring and CEO transition costs. FY27 revenue guidance of $336M-$341M aligns with market expectations, supported by a debt-free balance sheet.